View Post

Circulating Tumor Cells To Help Stage Metastatic Breast Cancer, New Research To Be Featured at ASCO Annual Meeting

In In The News by Barbara Jacoby

Study adds to significant body of evidence supporting clinical utility of CELLSEARCH Bologna, Italy and Huntingdon Valley, Pa., MAY 30, 2018 — Menarini Silicon Biosystems announced today that a new study has found that using circulating tumor cells (CTCs), a form of liquid biopsy, holds promise as a key tool for developing a staging system that can have a significant impact in …

View Post

Essential Eyebrow Solution® will meet with leading oncologists to discuss options for eyebrow hair preservation during cancer treatment

In In The News by Barbara Jacoby

EES – Essential Eyebrow Solution®, EES is the only cosmetic eyebrow product on the market proven to help combat eyebrow thinning.  It has been clinically tested for retention of eyebrows during chemotherapy with outstanding results. RMV Trademarks, LLC, manufacturer and distributor of EES, will be participating in the American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6 at McCormick …

View Post

Here’s What’s Next For Cancer-Killing T-Cells After Strong ASCO Showings

In In The News by Barbara Jacoby

By: Arlene Weintraub From: forbes.com The big news about chimeric antigen receptor T-cells (CARTs) at the American Society of Clinical Oncology meeting that just concluded in Chicago is that there was no earth-shattering news. Some analysts feared that predictions of FDA approvals as early as 2017 would prove overly optimistic for the technology, which involves removing immune-boosting T-cells from patients, …

View Post

Bristol-Myers Squibb Will Win Big with Melanoma Combination Immunotherapy, says GlobalData Analyst

In In The News by Barbara Jacoby

Bristol-Myers Squibb’s Opdivo/Yervoy immunotherapy combination likely to shape metastatic melanoma treatment landscape once approved Key opinion leaders ‘are enthusiastic about the efficacy of the combination, and foresee it as the future standard of care,’ says analyst Data presented at the recent American Society of Clinical Oncology (ASCO) Annual Meeting 2015 by Bristol-Myers Squibb (BMS) suggests that its Opdivo/Yervoy combination of …

View Post

New drugs from Bristol, Merck at forefront of cancer meeting

In In The News by Barbara Jacoby

By Deena Beasley and Bill Berkrot From: reuters.com New data to be released this weekend should help deepen the understanding of how broadly new drugs that unleash the body’s immune system to fight cancer can be used. Results from key clinical trials will be presented starting Friday in Chicago at the annual meeting of the American Society of Clinical Oncology. …

View Post

ONC201 Trial Featured in 2015 ASCO Conference

In In The News by Barbara Jacoby

Hummelstown, PA (May 26, 2015) – Oncoceutics, Inc. announced that details of a clinical phase I study in advanced solid tumors of its lead compound, ONC201, will be presented at the annual conference of the American Society of Clinical Oncology (ASCO) in Chicago on Saturday, May 30. The clinical study is being conducted at Rutgers Cancer Institute of New Jersey …

Sovaldi Vs. Cancer Drugs: Price And Value In The Pharmaceutical Industry

In In The News by Barbara Jacoby

By: Bernard Munos From: forbes.com The annual meeting of the American Society of Clinical Oncology is the venue where the pharmaceutical industry showcases its new drugs for cancer. For the last several years, these have been highly-anticipated events where stunning progress has been reported in treating a disease against which President Nixon declared war back in 1971. And each year’s …

More Bridges, More Options in Cancer Treatment – ASCO 2013 Wrap Up

In In The News, Uncategorized by Barbara Jacoby

POSTED IN Blog, Healthcare, Pharma The ASCO 2013 Annual Meeting has come to a close and the over 25,000 attendees have returned home armed with new ideas around the advances in cancer treatment. The conference highlighted immunotherapies, breakthrough drugs and difficult issues facing the oncology community. Immunotherapies were the hottest new topic in oncotherapy development, you expect to hear much …